title: Electrophysiologic effects of a potassium channel activator (pinacidil) on repolarization parameters in healthy volunteers: a surface ECG study.
abstract: About a quarter to a third of patients receiving pinacidil, a new cyanoguanidine vasodilator, show ECG changes, in particular T-wave modifications that sometimes mimic myocardial ischemia. To investigate these changes, we performed a randomized placebo-controlled trial in 10 carefully selected, healthy subjects who received single oral doses of either pinacidil (25 mg), quinidine (330 mg), and placebo. Quinidine, which induces specific modifications to the surface ECG signal, was used as an internal control. The complete experimental design involved five consecutive administrations of the drugs in random order: pinacidil (twice), quinidine (twice), and placebo (once), separated by a week-long washout period. Electrophysiologic data acquisition and signal analysis were performed with the Lyon vectocardiographic processing system. Pinacidil decreased T-wave amplitude (-0.26 +/- 0.1 mV) significantly as compared with placebo (-0.14 +/- 0.06 mV), but did not change the duration of the T-wave. Although the cardiac rate increased with pinacidil, the QTc interval remained constant. Conversely, quinidine did not modify the RR interval but significantly increased duration of the T-wave (+67 +/- 20 ms) and QTc interval (+53 +/- 13 ms) as compared with placebo (+17 +/- 13 and +18 +/- 11 ms). In addition, no specific ischemic changes to the T-loop were observed with pinacidil. The modifications to the surface ECG signal caused by pinacidil appear to be drug-specific and related to its electrophysiologic properties rather than involving any ischemic mechanism. Such an approach may be useful for describing morphologic ECG changes caused by new drugs and identifying possible underlying electrophysiologic mechanism(s), which should then be confirmed in further studies.
authors.affiliation: Clinical Pharmacology Unit, Cardiovascular Hospital, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Nony
authors.forename: P
authors.initials: P
authors.lastname: Girard
authors.forename: P
authors.initials: P
authors.lastname: Arnaud
authors.forename: P
authors.initials: P
authors.lastname: Rubel
authors.forename: J
authors.initials: J
authors.lastname: Fayn
authors.forename: B
authors.initials: B
authors.lastname: de Breyne
authors.forename: M C
authors.initials: MC
authors.lastname: Haugh
authors.forename: I
authors.initials: I
authors.lastname: Girard
authors.forename: S
authors.initials: S
authors.lastname: Ferry
authors.forename: J P
authors.initials: JP
authors.lastname: Boissel
mesh_terms: D000284:Administration, Oral; D000328:Adult; D004562:Electrocardiography / Q000187:drug effects*; D006146:Guanidines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D008297:Male; D020110:Pinacidil; D015221:Potassium Channels / Q000187:drug effects; D011802:Quinidine / Q000008:administration & dosage / Q000494:pharmacology; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D006146:Guanidines; D015221:Potassium Channels; D014665:Vasodilator Agents; D020110:Pinacidil; D011802:Quinidine